Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Gary Nachman maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold and lowers the price target from $91 to $90.
Canaccord Genuity analyst Gary Nachman maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold and lowers the price target from $91 to $90.